

# Gunhild Mari MÃ|landsmo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4692321/publications.pdf>

Version: 2024-02-01

78  
papers

3,629  
citations

257450

24  
h-index

138484

58  
g-index

81  
all docs

81  
docs citations

81  
times ranked

8153  
citing authors

#	ARTICLE	IF	CITATIONS
1	AXL inhibition improves BRAF-targeted treatment in melanoma. <i>Scientific Reports</i> , 2022, 12, 5076.	3.3	14
2	Serglycin Is Involved in TGF- $\beta$ 2 Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue. <i>Frontiers in Oncology</i> , 2022, 12, 868868.	2.8	6
3	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 25-39.	1.8	3
4	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	3.0	8
5	Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. <i>Molecular Therapy</i> , 2021, 29, 1199-1213.	8.2	16
6	Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. <i>JCO Precision Oncology</i> , 2021, 5, 286-306.	3.0	5
7	Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120217.	5.2	23
8	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6731.	3.3	5
9	Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft. <i>Nanomaterials</i> , 2021, 11, 1140.	4.1	7
10	MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. <i>Scientific Reports</i> , 2021, 11, 10893.	3.3	18
11	Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen. <i>Molecular Oncology</i> , 2021, 15, 2026-2045.	4.6	3
12	Immune checkpoint B7-3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. <i>Prostate</i> , 2021, 81, 838-848.	2.3	13
13	Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 671629.	2.8	3
14	EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition. <i>Molecular Cancer Research</i> , 2021, 19, 1546-1558.	3.4	6
15	Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model. <i>Biomacromolecules</i> , 2021, 22, 4169-4180.	5.4	7
16	Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer. <i>Npj Systems Biology and Applications</i> , 2021, 7, 36.	3.0	3
17	Novel human melanoma brain metastasis models in athymic nude fox1 nu mice: Site-specific metastasis patterns reflecting their clinical origin. <i>Cancer Medicine</i> , 2021, 10, 8604-8613.	2.8	2
18	Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. <i>International Journal of Cancer</i> , 2020, 146, 223-235.	5.1	13

#	ARTICLE	IF	CITATIONS
19	Soluble AXL as a marker of disease progression and survival in melanoma. PLoS ONE, 2020, 15, e0227187.	2.5	24
20	Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 590755.	2.8	6
21	Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma. Molecular Cancer Therapeutics, 2020, 19, 895-905.	4.1	21
22	Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. Acta Oncologica, 2020, 59, 733-740.	1.8	8
23	Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer. Biomacromolecules, 2020, 21, 1489-1498.	5.4	45
24	The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers. Scientific Reports, 2020, 10, 1277.	3.3	22
25	&lt;p&gt;Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy&lt;/p&gt;. International Journal of Nanomedicine, 2019, Volume 14, 6269-6285.	6.7	19
26	Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors. Archiv Der Pharmazie, 2019, 352, e1900101.	4.1	6
27	Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Research, 2019, 21, 9.	5.0	40
28	A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational Oncology, 2019, 12, 951-958.	3.7	7
29	Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. Breast Cancer Research, 2019, 21, 61.	5.0	42
30	p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Scientific Reports, 2019, 9, 5839.	3.3	28
31	Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer Immunology Research, 2019, 7, 701-706.	3.4	8
32	Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics. Frontiers in Oncology, 2019, 9, 1302.	2.8	9
33	Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. Journal of Controlled Release, 2019, 293, 183-192.	9.9	38
34	Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment. Cancer Letters, 2018, 439, 1-13.	7.2	6
35	Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease. BMC Cancer, 2018, 18, 739.	2.6	27
36	Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4. Molecular Oncology, 2018, 12, 1540-1558.	4.6	30

#	ARTICLE	IF	CITATIONS
37	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527
38	Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 127-137.	2.5	24
39	Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells. <i>Cell Death and Disease</i> , 2017, 8, e2769-e2769.	6.3	29
40	Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition. <i>Cancer Letters</i> , 2017, 396, 117-129.	7.2	45
41	Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. <i>ESMO Open</i> , 2017, 2, e000158.	4.5	8
42	Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 51-62.	3.3	16
43	Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts. <i>Molecular Imaging and Biology</i> , 2017, 19, 271-279.	2.6	4
44	Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 1513-1522.	3.0	12
45	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 185-198.	1.8	23
46	STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 91817-91827.	1.8	7
47	Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. <i>Oncotarget</i> , 2017, 8, 76290-76304.	1.8	23
48	Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. <i>Oncotarget</i> , 2017, 8, 76921-76934.	1.8	15
49	The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14033-e14033.	1.6	0
50	Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. <i>Diagnostic Pathology</i> , 2016, 11, 50.	2.0	10
51	hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma. <i>Cell Death Discovery</i> , 2016, 2, 16081.	4.7	11
52	Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 1840-1849.	2.8	11
53	Expression and clinical significance of Wee1 in colorectal cancer. <i>Tumor Biology</i> , 2016, 37, 12133-12140.	1.8	14
54	Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. <i>BMC Cancer</i> , 2016, 16, 191.	2.6	30

#	ARTICLE	IF	CITATIONS
55	Zebrafish as a model system for characterization of nanoparticles against cancer. <i>Nanoscale</i> , 2016, 8, 862-877.	5.6	74
56	Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma. <i>PLoS ONE</i> , 2016, 11, e0165382.	2.5	21
57	Low $\beta$ 2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. <i>Oncotarget</i> , 2016, 7, 1878-1894.	1.8	9
58	Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. <i>Oncotarget</i> , 2016, 7, 19997-20015.	1.8	25
59	<scp>STAMP</scp>2 increases oxidative stress and is critical for prostate cancer. <i>EMBO Molecular Medicine</i> , 2015, 7, 315-331.	6.9	52
60	Metabolic reprogramming supports the invasive phenotype in malignant melanoma. <i>Cancer Letters</i> , 2015, 366, 71-83.	7.2	70
61	In Vivo $^{31}\text{P}$ magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 601-609.	3.4	10
62	Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 755-767.	3.3	9
63	From autonomy to community; new perspectives on tumorigenicity and therapy resistance. <i>Cancer Treatment Reviews</i> , 2015, 41, 809-813.	7.7	2
64	Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. <i>Cancer Letters</i> , 2014, 344, 28-39.	7.2	46
65	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. <i>Cancer Discovery</i> , 2014, 4, 998-1013.	9.4	1,341
66	Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery. <i>Journal of Colloid and Interface Science</i> , 2014, 433, 76-85.	9.4	31
67	Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft. <i>PLoS ONE</i> , 2014, 9, e113278.	2.5	6
68	Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R16.	5.0	42
69	Dynamic $^{18}\text{F}$ -FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 173-180.	1.0	7
70	Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. <i>Molecular Oncology</i> , 2012, 6, 418-427.	4.6	19
71	In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1098-1107.	3.4	27
72	$\beta$ -H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. <i>International Journal of Cancer</i> , 2012, 130, 2282-2290.	5.1	128

#	ARTICLE	IF	CITATIONS
73	A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1665-1674.	4.2	44
74	Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. <i>BMC Cancer</i> , 2010, 10, 433.	2.6	93
75	Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma. <i>PLoS ONE</i> , 2010, 5, e10731.	2.5	73
76	Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 449-451.	3.3	22
77	Molecular profiling and characterization of luminal-like and basal-like <i>in vivo</i> breast cancer xenograft models. <i>Molecular Oncology</i> , 2009, 3, 469-482.	4.6	96
78	Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. <i>Journal of Gene Medicine</i> , 2005, 7, 307-315.	2.8	23